Pain Reduction in Cervical Dystonia Following Treatment with IncobotulinumtoxinA: A Pooled Analysis

Albanese, Alberto; Wissel, Jörg; Jost, Wolfgang H.; Castagna, Anna; Althaus, Michael; Comes, Georg; Scheschonka, Astrid; Vacchelli, Matteo; Jinnah, Hyder A.

doi:10.3390/toxins15050333

Cited by 4 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Repeated injections were administered in five of the six pooled studies. Multiple injection cycles of incobotulinumtoxinA have been shown to have a cumulative effect on DAS pain in spasticity [ 29 ] and pain in cervical dystonia [ 34 ]. Our analyses of the remaining three DAS domains showed that many patients had a maintained response to incobotulinumtoxinA at the time of reinjection.…”

Section: Discussionmentioning

confidence: 99%

Improvement in Quality-of-Life-Related Outcomes Following Treatment with IncobotulinumtoxinA in Adults with Limb Spasticity: A Pooled Analysis

Molteni,

Wissel,

Fheodoroff

et al. 2023

Toxins

Self Cite

View full text Add to dashboard Cite

A strong correlation has been reported between patient-reported quality of life (QoL) and the investigator-rated Disability Assessment Scale (DAS) in patients with spasticity. The current analysis evaluates the effect of incobotulinumtoxinA on QoL-related outcomes (limb position abnormality, as well as dressing- and hygiene-related disability, measured with the DAS) in adults with upper limb spasticity, using pooled data from six studies. Separate analyses for each DAS domain were performed using data from patients with disabilities for that domain (DAS score ≥1). Results showed that a significantly greater proportion of incobotulinumtoxinA-treated compared with placebo-treated patients achieved a ≥1-point reduction from baseline in each of the DAS domains (improvement) 4 weeks after the first injection. The benefits of incobotulinumtoxinA were observed regardless of the baseline severity of DAS impairment and of the time elapsed since stroke. The effects of incobotulinumtoxinA 4 weeks after injection were maintained or enhanced over multiple injection cycles for all three DAS domains, supporting the use of repeated injection cycles to provide sustained QoL benefit. IncobotulinumtoxinA represents an important treatment option to achieve better QoL-related outcomes for patients with upper limb spasticity, irrespective of the duration of their condition.

show abstract

Section: Discussionmentioning

confidence: 99%

Improvement in Quality-of-Life-Related Outcomes Following Treatment with IncobotulinumtoxinA in Adults with Limb Spasticity: A Pooled Analysis

Molteni,

Wissel,

Fheodoroff

et al. 2023

Toxins

Self Cite

View full text Add to dashboard Cite

show abstract

“…The published paper into this Special Issue described a pooling data from four studies in cervical dystonia adults treated with BoNT-A (incobotulinumtoxinA) for pain reduction [16].…”

mentioning

confidence: 99%

Botulinum Neurotoxins: From Toxin to Medicine

Santamato

2023

Toxins

View full text Add to dashboard Cite

show abstract

External Factors Modulating Pain and Pain‐Related Functional Impairment in Cervical Dystonia

Martino,

Achen,

Morgante

et al. 2024

Movement Disord Clin Pract

View full text Add to dashboard Cite

BackgroundLittle is known about factors modulating pain and pain‐related functional impairment in isolated cervical dystonia (CD).ObjectiveThe aim was to assess the prevalence and interrelationship between pain‐modulating factors and pain‐related determinants of functional impairment and quality of life in CD.MethodsWe analyzed pain‐aggravating and pain‐relieving external factors, the degree of pain‐related functional impact on routine activities, and the relationship between these and pain severity, using cross‐sectional data collected using the Pain in Dystonia Scale (PIDS) from 85 participants with CD. Pairwise correlation analyses and age‐ and sex‐adjusted linear regression models estimated the relationship between pain‐modulating factors and pain severity, and the impact of pain severity, dystonia severity, and psychiatric symptoms on pain‐related functional impairment and disease‐specific quality of life (measured using the Craniocervical Dystonia Questionnaire‐24).ResultsStress and prolonged fixed position were the most frequent and impacting pain triggers, with women reporting larger impact. The average impact of pain‐relieving factors was lower than that of pain triggers. Physical exercise and social gatherings were the most impacted activities by pain in CD. The intensity of external modulating factors was a predictor of pain severity. Severity of pain, CD, and psychiatric symptoms independently predicted pain‐related functional impairment, whereas quality of life was predicted by pain severity, pain‐related functional impairment, and psychiatric symptom severity, but not dystonia severity.ConclusionThe PIDS provides insight into external modulation and functional impact of pain in CD. The pattern of external modulation of pain in CD is in line with a multifactorial modulation and complex physiology.

show abstract

Pain Reduction in Cervical Dystonia Following Treatment with IncobotulinumtoxinA: A Pooled Analysis

Cited by 4 publications

References 49 publications

Improvement in Quality-of-Life-Related Outcomes Following Treatment with IncobotulinumtoxinA in Adults with Limb Spasticity: A Pooled Analysis

Improvement in Quality-of-Life-Related Outcomes Following Treatment with IncobotulinumtoxinA in Adults with Limb Spasticity: A Pooled Analysis

Botulinum Neurotoxins: From Toxin to Medicine

External Factors Modulating Pain and Pain‐Related Functional Impairment in Cervical Dystonia

Contact Info

Product

Resources

About